ezetimibe

Summary

Summary: An azetidine derivative and ANTICHOLESTEREMIC AGENT that inhibits intestinal STEROL absorption. It is used to reduce total CHOLESTEROL; LDL CHOLESTEROL, and APOLIPOPROTEINS B in the treatment of HYPERLIPIDEMIAS.

Top Publications

  1. Choby B. Diabetes Update: Prevention and Management of Diabetes Complications. FP Essent. 2017;456:36-40 pubmed
    ..Patients with diabetes and a history of ASCVD should be treated with high-dose statins. A combination of ezetimibe and a moderate-dose statin is an option for patients who cannot tolerate high-dose therapy...
  2. Filippatos T, Elisaf M. Effects of ezetimibe/simvastatin combination on metabolic parameters. Int J Cardiol. 2016;202:273-4 pubmed publisher
  3. Lønnebakken M, de Simone G, Saeed S, Boman K, Rossebø A, Bahlmann E, et al. Impact of stroke volume on cardiovascular risk during progression of aortic valve stenosis. Heart. 2017;103:1443-1448 pubmed publisher
    ..In 1671 patients from the Simvastatin Ezetimibe in Aortic Stenosis (SEAS) study, the association of stroke volume indexed for body surface area (SVI) with major ..
  4. Schmidt A, Pearce L, Wilkins J, Overington J, Hingorani A, Casas J. PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2017;4:CD011748 pubmed publisher
    ..We compared PCSK9 inhibitors with placebo (thirteen RCTs), ezetimibe (two RCTs) or ezetimibe and statins (five RCTs).Compared with placebo, PCSK9 inhibitors decreased LDL-C by 53...
  5. Dimova L, de Boer J, Plantinga J, Plösch T, Hoekstra M, Verkade H, et al. Inhibiting Cholesterol Absorption During Lactation Programs Future Intestinal Absorption of Cholesterol in Adult Mice. Gastroenterology. 2017;153:382-385.e3 pubmed publisher
    ..in milk fed to newborn mice by supplementing the food of dams (for 3 weeks between birth and weaning) with ezetimibe, which is secreted into milk...
  6. El Shahawy M, Cannon C, Blom D, McKenney J, Cariou B, Lecorps G, et al. Efficacy and Safety of Alirocumab Versus Ezetimibe Over 2 Years (from ODYSSEY COMBO II). Am J Cardiol. 2017;120:931-939 pubmed publisher
    ..The COMBO II trial compared the efficacy and safety of alirocumab versus ezetimibe over 2 years. A prespecified first analysis was reported at 52 weeks...
  7. Thomassen H, Cioffi G, Gerdts E, Einarsen E, Midtbø H, Mancusi C, et al. Echocardiographic aortic valve calcification and outcomes in women and men with aortic stenosis. Heart. 2017;103:1619-1624 pubmed publisher
    ..and grouped into none/mild or moderate/severe AVC in 1725 men and women with asymptomatic AS in the Simvastatin Ezetimibe in Aortic Stenosis study...
  8. Stanifer J, Charytan D, White J, Lokhnygina Y, Cannon C, Roe M, et al. Benefit of Ezetimibe Added to Simvastatin in Reduced Kidney Function. J Am Soc Nephrol. 2017;28:3034-3043 pubmed publisher
    ..The strongest evidence supporting the cardiovascular benefit of statins in individuals with CKD was shown with ezetimibe plus simvastatin versus placebo...
  9. Skolnik N, Jaffa F, Kalyani R, Johnson E, Shubrook J. Reducing CV risk in diabetes: An ADA update. J Fam Pract. 2017;66:300-308 pubmed
    ..This Q&A highlights changes to the ADA's 2017 Standards of Care to help you fine-tune your approach to patients who have, or are at risk for, atherosclerotic CV disease. ..

More Information

Publications20

  1. Al Kindi M, Bélanger A, Sayegh K, Senouci S, Aljenedil S, Sivakumaran L, et al. Aortic Calcification Progression in Heterozygote Familial Hypercholesterolemia. Can J Cardiol. 2017;33:658-665 pubmed publisher
    ..Mean LDL cholesterol (LDL-C) during treatment was 2.53 mmol/L; all patients were receiving high-dose statin/ezetimibe; 5 of 16 were receiving evolocumab. Baseline LDL-C was 7.6 ± 1.3 mmol/L...
  2. Nobecourt E, Cariou B, Lambert G, Krempf M. Severe decrease in high-density lipoprotein cholesterol with the combination of fibrates and ezetimibe: A case series. J Clin Lipidol. 2017;11:289-293 pubmed publisher
    ..Three of the patients were treated with fibrates and had a sudden decrease in HDL-C after the adjunction of ezetimibe. HDL-C returned to normal levels after discontinuation of the offending therapies...
  3. Kamishikiryo J, Haraguchi M, Nakashima S, Tasaka Y, Narahara H, Sugihara N, et al. N-terminal domain of the cholesterol transporter Niemann-Pick C1-like 1 (NPC1L1) is essential for ?-tocopherol transport. Biochem Biophys Res Commun. 2017;486:476-480 pubmed publisher
    ..of cells that stably express NPC1L1-GFP with ?-tocopherol promotes NPC1L1 endocytosis, and the NPC1L1 inhibitor, ezetimibe, efficiently prevents the ?-tocopherol-induced endocytosis of NPC1L1...
  4. Correia L. Ezetimibe: Clinical and Scientific Meaning of the IMPROVE-IT Study. Arq Bras Cardiol. 2016;106:247-9 pubmed publisher
  5. Ueda S, Miyake I, Takata K, Shimizu N, Shirotani K, Ishida S, et al. Ezetimibe, an inhibitor of intestinal cholesterol absorption, decreases serum level of malondialdehyde-modified low-density lipoprotein in patients with hypercholesterolemia. Int J Cardiol. 2011;146:420-1 pubmed publisher
  6. Sharp Collaborative Group -. Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease. Am Heart J. 2010;160:785-794.e10 pubmed publisher
    ..no known history of myocardial infarction or coronary revascularization were randomized in a ratio of 4:4:1 to ezetimibe 10 mg plus simvastatin 20 mg daily versus matching placebo versus simvastatin 20 mg daily (with the latter arm ..
  7. Madonna R, Renna F, Lanuti P, Perfetti M, Marchisio M, Briguori C, et al. The acute impact of high-dose lipid-lowering treatment on endothelial progenitor cells in patients with coronary artery disease-The REMEDY-EPC early substudy. PLoS ONE. 2017;12:e0172800 pubmed publisher
    ..We evaluated whether pre-procedural exposure to different lipid-lowering drugs (statins±ezetimibe) can acutely increase levels/activity of EPCs/CECs in patients with stable coronary artery disease (CAD)...
  8. Real Hernandez L, Gonzalez de Mejia E. Bean peptides have higher in silico binding affinities than ezetimibe for the N-terminal domain of cholesterol receptor Niemann-Pick C1 Like-1. Peptides. 2017;90:83-89 pubmed publisher
    ..triplicate to the N-terminal domain using docking program AutoDock Vina, and results were compared to those of ezetimibe, a prescribed NPC1L1 inhibitor. Three black bean peptides (-7.2 to -7...
  9. Gohlke Bärwolf C, Minners J, Jander N, Gerdts E, Wachtell K, Ray S, et al. Natural history of mild and of moderate aortic stenosis-new insights from a large prospective European study. Curr Probl Cardiol. 2013;38:365-409 pubmed publisher
    ..In the Simvastatin and Ezetimibe in Aortic Stenosis study, with the exception of hypertension, comorbidities were excluded, thus allowing an ..
  10. Othman R, Myrie S, Mymin D, Roullet J, DeBarber A, Steiner R, et al. Thyroid Hormone Status in Sitosterolemia Is Modified by Ezetimibe. J Pediatr. 2017;188:198-204.e1 pubmed publisher
    ..the association between biomarkers of thyroid status and 5?-stanols in patients with sitosterolemia treated with ezetimibe (EZE)...
  11. Harangi M, Seres I, Balogh I, Köbling T, Harangi J, Varga J, et al. Effect of apolipoprotein E genotypes on the efficacy of ezetimibe monotherapy in patients with statin induced adverse effects. Int J Clin Pharmacol Ther. 2013;51:746-52 pubmed publisher
    ..clarify the effect of Apolipoprotein E (ApoE) polymorphism on the efficacy of cholesterol absorption inhibitor ezetimibe monotherapy on lipid parameters...